1221. Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology Group

1222. Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: reduction post-bortezomib monotherapy

1223. Pattern of failure and survival of patients with metastatic urothelial tumors relapsing after cis-platinum-based chemotherapy

1224. The combination of gemcitabine and carboplatin as first-line treatment in patients with advanced urothelial carcinoma: A Phase II study of the Hellenic Cooperative Oncology Group

1225. Prunart Renal Lymphoma: A Clinical and Radiological Study

1226. Dickkopf-1: a suitable target for the management of myeloma bone disease

1227. Effects of rosuvastatin on myeloperoxidase levels in patients with chronic heart failure: a randomized placebo-controlled study

1228. Successful conservative treatment of neutropenic enterocolitis complicating taxane-based chemotherapy: a report of five cases

1229. Paclitaxel and gemcitabine versus carboplatin and gemcitabine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group

1230. Combination of LHRH analog with somatostatin analog and dexamethasone versus chemotherapy in hormone-refractory prostate cancer: a randomized phase II study

1231. Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer

1232. Gemcitabine versus gemcitabine--carboplatin for patients with advanced non-small cell lung cancer and a performance status of 2: a prospective randomized phase II study of the Hellenic Cooperative Oncology Group

1233. Effects of rosuvastatin and allopurinol on circulating endothelial progenitor cells in patients with congestive heart failure: the impact of inflammatory process and oxidative stress

1234. Significant differences of lymphocytes isolated from ascites of patients with ovarian cancer compared to blood and tumor lymphocytes. Association of CD3+ CD56+ cells with platinum resistance

1235. Multiple myeloma in elderly patients: prognostic factors and outcome

1236. Increased bone mineral density in a subset of patients with relapsed multiple myeloma who received the combination of bortezomib, dexamethasone and zoledronic acid

1237. Anthracycline-based chemotherapy of primary non-Hodgkin’s lymphoma of the testis: the hellenic cooperative oncology group experience

1238. Favorable outcome of ovarian germ cell malignancies treated with cisplatin or carboplatin-based chemotherapy: a Hellenic Cooperative Oncology Group study

1239. Minichromosome maintenance proteins 2 and 5 in non-benign epithelial ovarian tumours: relationship with cell cycle regulators and prognostic implications

1240. Rituximab therapy in monoclonal IgM-related neuropathies